Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation
Anna Murzyn, Anna Krasowska, Piotr Stefanowicz, Dorota Dziadkowiec, Marcin Łukaszewicz, Anna Murzyn, Anna Krasowska, Piotr Stefanowicz, Dorota Dziadkowiec, Marcin Łukaszewicz
Abstract
Candidiasis are life-threatening systemic fungal diseases, especially of gastro intestinal track, skin and mucous membranes lining various body cavities like the nostrils, the mouth, the lips, the eyelids, the ears or the genital area. Due to increasing resistance of candidiasis to existing drugs, it is very important to look for new strategies helping the treatment of such fungal diseases. One promising strategy is the use of the probiotic microorganisms, which when administered in adequate amounts confer a health benefit. Such a probiotic microorganism is yeast Saccharomyces boulardii, a close relative of baker yeast. Saccharomyces boulardii cells and their extract affect the virulence factors of the important human fungal pathogen C. albicans, its hyphae formation, adhesion and biofilm development. Extract prepared from S. boulardii culture filtrate was fractionated and GC-MS analysis showed that the active fraction contained, apart from 2-phenylethanol, caproic, caprylic and capric acid whose presence was confirmed by ESI-MS analysis. Biological activity was tested on C. albicans using extract and pure identified compounds. Our study demonstrated that this probiotic yeast secretes into the medium active compounds reducing candidal virulence factors. The chief compound inhibiting filamentous C. albicans growth comparably to S. boulardii extract was capric acid, which is thus responsible for inhibition of hyphae formation. It also reduced candidal adhesion and biofilm formation, though three times less than the extract, which thus contains other factors suppressing C. albicans adherence. The expression profile of selected genes associated with C. albicans virulence by real-time PCR showed a reduced expression of HWP1, INO1 and CSH1 genes in C. albicans cells treated with capric acid and S. boulardii extract. Hence capric acid secreted by S. boulardii is responsible for inhibition of C. albicans filamentation and partially also adhesion and biofilm formation.
Conflict of interest statement
Competing Interests: This work was partly supported by a grant from Biocodex, France, which initiated research on Sacchromyces boulardii. However the funding ended long before the authors were able to identify the active compound described in the paper. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Figures
References
- Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981–988.
- Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:583–590.
- Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517–523.
- Saint-Marc T, Rossello-Prats L, Touraine JL. [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS]. Ann Med Interne (Paris) 1991;142:64–65.
- Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP- and Ca2+ -dependent Cl- secretion in T84 cells. Dig Dis Sci. 1999;44:2359–2368.
- Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, et al. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 2006;60:24–29.
- Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67:302–307.
- Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1994;36:522–527.
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163.
- Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol. 2001;9:327–335.
- Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. Nonfilamentous C. albicans mutants are avirulent. Cell. 1997;90:939–949.
- Braun BR, Johnson AD. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science. 1997;277:105–109.
- Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2004;17:255–267.
- Southern P, Horbul J, Maher D, Davis DA. C. albicans colonization of human mucosal surfaces. PLoS One. 2008;3:e2067.
- Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003;67:400–428, table of contents.
- Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev. 2000;13:122–143, table of contents.
- Martins M, Henriques M, Azeredo J, Rocha SM, Coimbra MA, et al. Morphogenesis control in Candida albicans and Candida dubliniensis through signaling molecules produced by planktonic and biofilm cells. Eukaryot Cell. 2007;6:2429–2436.
- McLain N, Ascanio R, Baker C, Strohaver RA, Dolan JW. Undecylenic acid inhibits morphogenesis of Candida albicans. Antimicrob Agents Chemother. 2000;44:2873–2875.
- Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother. 1972;2:23–28.
- Ells R, Kock JL, Van Wyk PW, Botes PJ, Pohl CH. Arachidonic acid increases antifungal susceptibility of Candida albicans and Candida dubliniensis. J Antimicrob Chemother. 2009;63:124–128.
- Bergsson G, Arnfinnsson J, Steingrimsson O, Thormar H. In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother. 2001;45:3209–3212.
- Clement M, Tremblay J, Lange M, Thibodeau J, Belhumeur P. Whey-derived free fatty acids suppress the germination of Candida albicans in vitro. FEMS Yeast Res. 2007;7:276–285.
- Jawhara S, Poulain D. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol. 2007;45:691–700.
- Fidan I, Kalkanci A, Yesilyurt E, Yalcin B, Erdal B, et al. Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses. 2009;52:29–34.
- Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis. 1993;168:1314–1318.
- Krasowska A, Murzyn A, Dyjankiewicz A, Lukaszewicz M, Dziadkowiec D. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Res. 2009;9:1312–1321.
- Konno N, Ishii M, Nagai A, Watanabe T, Ogasawara A, et al. Mechanism of Candida albicans transformation in response to changes of pH. Biol Pharm Bull. 2006;29:923–926.
- Nobile CJ, Nett JE, Andes DR, Mitchell AP. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot Cell. 2006;5:1604–1610.
- Ene IV, Bennett RJ. Hwp1 and related adhesins contribute to both mating and biofilm formation in Candida albicans. Eukaryot Cell. 2009;8:1909–1913.
- Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002;68:5459–5463.
- Sharkey LL, McNemar MD, Saporito-Irwin SM, Sypherd PS, Fonzi WA. HWP1 functions in the morphological development of Candida albicans downstream of EFG1, TUP1, and RBF1. J Bacteriol. 1999;181:5273–5279.
- Mille C, Janbon G, Delplace F, Ibata-Ombetta S, Gaillardin C, et al. Inactivation of CaMIT1 inhibits Candida albicans phospholipomannan beta-mannosylation, reduces virulence, and alters cell wall protein beta-mannosylation. J Biol Chem. 2004;279:47952–47960.
- Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother. 2003;47:1220–1227.
- Cao YY, Cao YB, Xu Z, Ying K, Li Y, et al. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother. 2005;49:584–589.
- Singleton DR, Masuoka J, Hazen KC. Cloning and analysis of a Candida albicans gene that affects cell surface hydrophobicity. J Bacteriol. 2001;183:3582–3588.
- Singleton DR, Fidel PL, Jr, Wozniak KL, Hazen KC. Contribution of cell surface hydrophobicity protein 1 (Csh1p) to virulence of hydrophobic Candida albicans serotype A cells. FEMS Microbiol Lett. 2005;244:373–377.
- Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet. 1984;198:179–182.
Source: PubMed